Related Experiment Video

Updated: Sep 24, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K

Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung Cancer

Sha Liu1, Tao Pan1, Ming-Kun Wang1

  • 1Department of Radiotherapy, The First Affiliated Hospital of Hainan Medical University, Haikou, 570216, China.

Clinical Drug Investigation
|May 5, 2022
PubMed
Abstract

Insights

Adding bevacizumab to osimertinib significantly improved outcomes for patients with EGFR T790M-mutated non-small cell lung cancer (NSCLC). The combination therapy demonstrated enhanced overall survival and progression-free survival compared to osimertinib alone.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Medicine

Background:

  • Osimertinib is a targeted therapy for non-small cell lung cancer (NSCLC) with EGFR T790M mutations.
  • The combination of osimertinib and bevacizumab's efficacy and safety in this patient population remains largely unelucidated.

Purpose of the Study:

  • To evaluate the additional therapeutic effect of bevacizumab combined with osimertinib versus osimertinib monotherapy.
  • To compare overall survival (OS), progression-free survival (PFS), and adverse events (AEs) in NSCLC patients with EGFR T790M mutations.

Main Methods:

  • A comparative study involving 32 patients receiving osimertinib alone and 20 patients receiving osimertinib plus bevacizumab.
  • Median follow-up of 12 months, with estimations of OS and PFS.
  • Systematic comparison of adverse events between the two treatment arms.

Main Results:

  • The combination group showed a higher overall response rate (70.0% vs. 43.8%).
  • Osimertinib plus bevacizumab significantly improved OS (p=0.038) and PFS (p=0.045) compared to osimertinib alone.
  • Hypertension was a significantly more frequent AE in the combination group (p=0.003), with no significant increase in other AEs.

Conclusions:

  • Concomitant bevacizumab and osimertinib may offer a potential therapeutic advantage over osimertinib monotherapy in EGFR T790M-mutated NSCLC.
  • Further large-scale studies are required to validate these findings and confirm the therapeutic potential.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
682
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
234